^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HS627 (pertuzumab biosimilar)

    i
    Other names: HS627
    Associations

    News

    Trials
    Company:
    Zhejiang Hisun
    Drug class:
    HER2 dimerization inhibitor
    Related drugs:
    Associations

    News

    Trials
    over4years
    Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel (clinicaltrials.gov)
    P3, N=408, Recruiting, Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd
    Clinical • New P3 trial • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • HS627 (pertuzumab biosimilar)